$18.9
0%
Price vs. BitRank (Last 150 days)
Data gathered: February 22
Data gathered: February 22
Data Bits
| Job Posts | N/A | N/A |
| Total Followers [beta] | N/A | N/A |
| Sentiment | N/A | N/A |
| Customer reviews | N/A | N/A |
| Linkedin Employees | N/A | N/A |
| 4chan Mentions | N/A | N/A |
| Stocktwits Mentions | N/A | N/A |
| Stocktwits Subscribers | N/A | N/A |
| News Mentions | N/A | N/A |
| Reddit Mentions | N/A | N/A |
In the news
About Aktis Oncology
Aktis Oncology (Nasdaq: AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies.
| BitRank | / 100 |
| Price | $18.9 |
| Industry | Biotechnology |
Similar companies
| Company | Price | BitRank | |
|---|---|---|---|
Financial performance
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
|---|---|---|---|---|---|
| Q3 '24 | 9M | 4.7M | 4.3M | -6.4M | -5.1M |
| Q2 '24 | 5.9M | 6.5M | -640,000 | -109M | -105M |
| Q1 '24 | 7.5M | 7.2M | 350,000 | -23M | -20M |
| Q4 '23 | 7M | 6.3M | 680,000 | -16M | -12M |
| Q3 '23 | 7M | 8.1M | -1.1M | -20M | -17M |
Insider Transactions
| Kim Helen Susan filed to buy 157,387 shares at $18. January 12 '26 |
| Vida Ventures II, LLC filed to buy 157,387 shares at $18. January 12 '26 |
| NODELMAN OLEG filed to buy 347,305 shares at $18. January 12 '26 |
| Kim Helen Susan filed to buy 5,671,825 shares at $18. January 12 '26 |
| Vida Ventures II, LLC filed to buy 5,671,825 shares at $18. January 12 '26 |
Read more about Aktis Oncology and their job posts, total followers [beta], sentiment, customer reviews, linkedin employees, 4chan mentions, stocktwits mentions, stocktwits subscribers, news mentions, reddit mentions.